European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.

AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer

ESMO 2014 – Prostate Cancer

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

ESMO 2014 – Prostate Cancer

Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response

ESMO 2014 – Prostate Cancer

Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer

ESMO 2014 – Prostate Cancer

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 – Immuno-Oncology

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 – Immuno-Oncology

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 – Immuno-Oncology

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 – Immuno-Oncology

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Page 12 of 13

9
10
11
12
13